The diagnostic and prognostic utility of prostate-specific antigen for diseases of the breast

Breast Cancer Research and Treatment

Volumn 59, Issue 1, 2000, Pages 1-14

  Black, Margot H ^c   Diamandis, Eleftherios P ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b MOUNT SINAI HOSPITAL   (Canada)

^c NONE

Author keywords

Benign breast disease; Breast cancer; Breast cyst; Molecular forms of prostate specific antigen; Prognostic indicators; Prostate specific antigen; Tumor markers

Indexed keywords

KALLIKREIN; PROSTATE SPECIFIC ANTIGEN; STEROID RECEPTOR; TAMOXIFEN; TUMOR MARKER;

BREAST CANCER; BREAST CYST; BREAST DISEASE; BREAST TUMOR; CANCER RISK; FEMALE; HUMAN; HUMAN TISSUE; NIPPLE; PRIORITY JOURNAL; PROGNOSIS; REVIEW;

BREAST NEOPLASMS; FEMALE; HUMANS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; TUMOR MARKERS, BIOLOGICAL;

EID: 0002413074     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006380306781     Document Type: Review

References (146)

1. Riegman PHJ, Vlietstra RJ, Suurmeijer L, Cleutjens CBJM, Trapman J: Characterization of the human kallikrein locus. Genomics 14:6-11, 1992
2. Clements JA: The human kallikrein gene family: a diversity of expression and function. Mol Cell Endocrinol 99: C1-6, 1994
3. Yousef GM, Luo L-Y, Diamandis EP: Identification of novel human kallikrein-like genes on chromosome 19q13.3-q13.4. Anticancer Res (in press)
4. Dube JY: Tissue kallikreins and prostatic diseases in man: new questions. Biochem Cell Biol 70: 177-178, 1992
5. Deperthes D, Marceau F, Frenette G, Lazure C, Tremblay RR, Dube JY: Human kallikrein hK2 has low kininogenase activity while prostate-specific antigen (hK3) has none. Biochim Biophys Acta 1343: 102-106, 1997
6. MacDonald RJ, Margolius HS, Erdos EG: Molecular biology of tissue kallikrein. Biochem J 253: 313-321, 1988
7. Berg T, Bradshaw RA, Carretero OA, Chao J, Chao L, Clements JA, Fahnestock M, Fritz H, Gauthier F, MacDonald RJ: A common nomenclature for members of the tissue (glandular) kallikrein gene families. Recent progress on kinins. Agents Actions 38 (suppl 1): 19-25, 1992
8. Fukushima D, Kitamura N, Nakanishi S: Nucleotide sequence of cloned cDNA for human pancreatic kallikrein. Biochemistry 24: 8037-8043, 1985
9. Schedlich LJ, Bennetts BH, Morris BJ: Primary structure of a human glandular kallikrein gene. DNA 6: 429-437, 1987
10. Chapdelaine P, Paradis G, Tremblay RR, Dube JY: High level expression in the prostate of a human glandular kallikrein mRNA related to prostate-specific antigen. FEBS Lett 236: 205-208, 1988
11. Kumar A, Mikolajczyc SD, Goel AS, Millar LS, Saedi MS: Expression of pro form of prostate-specific antigen by mammalian cells and its conversion to mature, active form by human kallikrein 2. Cancer Res 57: 3111-3114, 1997
12. Lovgren J, Rajakoski K, Kaip M, Lundwall A, Lilja H: Activation of the zymogen form of prostate-specific antigen by human glandular kallikrein 2. Biochem Biophys Res Comm 238: 549-555, 1997
13. Takayama TK, Fujikawa K, Davie EW: Characterization of the precursor of prostate-specific antigen. J Biol Chem 272: 21582-21588, 1997
14. Watt KW, Lee PJL, M'Timkulu TM, Chan WP, Loor R: Human prostate-specific antigen: structural and functional similarity with serine proteases. Proc Natl Acad Sci USA 83: 3166-3170, 1986
15. Akiyama K, Nakamura T, Iwanaga S, Hara M: The chymotrypsin-like activity of human prostate-specific antigen, γ-seminoprotein. FEBS Lett 225: 168-172, 1987
16. Frankel AE, Rouse RV, Wang MC, Chu TM, Herzenber LA: Monoclonal antibody to a human prostate antigen. Cancer Res 42: 3714-3718, 1982
17. Sinha AA, Wilson MJ, Gleason DF: Immunoelectron microscopic localization of prostate-specific antigen in human prostate by the Protein A-gold complex. Cancer 60: 1288-1293, 1987
18. Sensabaugh GF: Isolation and characterization of a semen-specific protein from human seminal plasma: A potential new marker for semen identification. J Forensic Sci 23: 106-115, 1978
19. Lilja H, Oldbring J, Rannevik G, Laurell C-B: Seminal vesicle-secreted proteins and their reactions during gelation and liquefaction of human semen. J Clin Invest 80: 281-285, 1993
20. Ohlsson K, Bjartell A, Lilja H: Secretory leucocyte protease inhibitor in the male genital tract: PSA-induced proteolytic processing in human semen and tissue localization. J Androl 16: 64-74, 1995
21. Christensson A, Laurell CB, Lilja H: Enzymatic activity of the prostate-specific antigen and its reactions with extracellular serine protease inhibitors. Eur J Biochem 194: 755-763, 1990
22. Kuriyama M, Wang MC, Papsidero LD, Killian CS, Shimano T, Valenzuela L, Nishiura T, Murphy GP, Chu T: Quantitation of prostate-specific antigen in serum by a sensitive enzyme immunoassay. Cancer Res 40: 4658-4662, 1980
23. Lilja H, Christensson A, Dahlen U, Matikainen MT, Nilsson O, Pettersson K, Lovgren T: Prostate-specific antigen in human serum occurs predominantly in a complex with αl-antichymotrypsin. Clin Chem 37: 1618-1625, 1991
24. Lilja H: Regulation of the enzymatic activity of prostate-specific antigen and its reactions with extracellular protease inhibitors in prostate cancer. Scand J Clin Lab Invest Supp 220: 45-56, 1995
25. Mikolajczvk SD, Grauer LS, Millar LS, Hill TM, Kumar A, Rittenhouse HG, Wolfert RL, Saedi MS: A precursor form of PSA (pPSA) is a component of the free PSA in prostate cancer serum. Urology 50: 710-714, 1997
26. Noldus J, Chen Z, Stamey TA: Isolation and characterization of free form prostate-specific antigen (f-PSA) in sera of men with prostate cancer. J Urol 158: 1606-1609, 1997
27. Papsidero LD, Wang MC, Valenzuela LA, Murphy GP, Chu TM: A prostate antigen in sera of prostatic cancer patients. Cancer Res 40: 2428-2432, 1980
28. Montie JE and Meyers SE: Defining the ideal tumor marker for prostate cancer. Urol Clin N Am 24: 247-252, 1997
29. Armbruster DA: Prostate-specific antigen: biochemistry, analytical methods, and clinical application. Clin Chem 39: 181-195, 1993
30. Yu H, Diamandis EP: Ultrasensitive time-resolved immunofluorometric assay of prostate-specific antigen in serum and preliminary clinical studies. Clin Chem 39: 2108-2114, 1993
31. Stenman UH, Leinonen J, Alfthan H, Rannikko S, Tuhkanen K, Alfthan O: A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in scrum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res 51: 222-226, 1991
32. Partin AW, Kelly CA, Subong ENP, Walsh PC, Chan DW, Wang TJ, Rittenhouse HG, Wolfert RL, Norton KC, McCormack R: Measurement of the ratio of free PSA to total improves prostate cancer detection for men with total PSA levels between 4 and 10 ng/mL. J Urol 153: 295A, 1995
33. Young CY, Seay T, Hogen K, Charlesworth MC, Roche PC, Klee GG, Tindall DJ: Prostate-specific human kallikrein (hK2) as a novel marker for prostate cancer. Prostate Suppl 7: 17-24, 1996
34. Charlesworth MC, Young CY, Klee GG, Saedi MS, Mikolajczyk SD, Finlay JA, Tindall DJ: Detection of a prostate-specific protein, human glandular kallikrein (hK2), in sera of patients with elevated prostate-specific antigen levels. Urology 49: 487-493, 1997
35. Black MH, Magklara A, Obiezu CV, Melegos DN, Wolfert RL, Diamandis EP: Development of an ultrasensitive immunoassay for human glandular kallikrein with no cross-reactivity with prostate-specific antigen. Clin Chem 45: 790-799, 1999
36. Klee GG, Goodmanson MK, Jacobson SJ, Young CY, Finlay JA, Rittenhouse HG, Wolfert RL, Tindall DJ: Highly sensitive automated chemiluminometric assay for measuring free human glandular kallikrein-2. Clin Chem 45: 800-806, 1999
37. Stenman U-H: New ultrasensitive assays facilitate studies on the role of human glandular kallikrein (hK2) as a marker for prostatic disease. Clin Chem 45: 753-754, 1999
38. Pollen JJ and Dreilinger A: Immunohistochemical identification of prostatic acid phosphatase and prostate-specific antigen in female periurethral glands. Urology 23: 303-304, 1984
39. Tepper SL, Jagirdar J, Heath D, Geller SA: Homology between the female paraurethral (Skene's) glands and the prostate. Immuno-histochemical demonstration. Arch Pathol Lab Med 108: 423-425, 1984
40. Wernert N, Albrech M, Sesterhenn I, Goebbels R, Bonkhoff H, Seitz G, Inniger R, Remberger K: The 'female prostate'. Location, morphology, immunohistochemical characteristics and significance. Eur Urol 22: 64-69, 1992
41. Svanholm H, Andersen OP, Rohl H: Tumour of female paraurethral duct. Immunohistochemical similarity with prostatic carcinoma. Virchowas Arch A Pathol Anat Histopathol 411: 395-398, 1987
42. Spencer JR, Brodin AG, Ignatoff JM: Clear cell adenocarcinoma of the urethra: evidence for origin within paraurethral ducts. J Urol 143: 122-125, 1990
43. Zaviacic M, Sidlo J, Borovsky M: Prostate-specific antigen and prostate-specific acid phosphatase in adenocarcinoma of Skene's paraurethral glands and ducts. Virchows Arch 423: 503-505, 1993
44. Ebisuno S, Miyai M, Tomofumi N: Clear cell adenocarcinoma of the female urethra showing positive staining with antibodies to prostate-specific antigen and prostatic acid phosphatase. Urology 45: 682-685, 1995
45. Papotti M, Paties C, Peveri V, Moscuzza L, Bussolati G: Immunocytochemical detection of prostate-specific antigen (PSA) in skin and breast tissues and tumours. Basic Appl Histochem 33: 25-29, 1989
46. Golz R, Schubert GE: Prostatic specific antigen. Immunoreactivity in urachal remnants. J Urol 141: 1480-1482, 1989
47. Minkowittz G, Peterson P, Godwin TA: A histochemical and immunohistochemical study of adenocarcinomas involving urinary bladder. Mod Pathol 3: 68A, 1990
48. Grignon DJ, Ro JY, Ayala AC, Johnson DE, Ordonez NG: Primary adenocarcinoma of the urinary bladder: a clinico-pathologic analysis of 72 cases. Cancer 67: 2165-2172, 1991
49. Ishikawa T, Kashiwagi H, Iwakami Y, Hirai M, Kawamura T, Aiyoshi Y, Yashiro T, Ami Y, Uchida K, Miwa M: Expression of alpha-fetoprotein and prostate-specific antigen genes in several tissues and detection of mRNAs in normal circulating blood by reverse transcriptase-polymerase chain reaction. Jpn J Clin Oncol 28: 723-728, 1998
50. Kamoshida S, Tsutsumi Y: Extraprostatic localization of prostatic acid phosphatase and prostate-specific antigen: distribution in cloacogenic glandular epithelium and sex-dependent expression in human anal gland. Hum Pathol 21: 1108-1111, 1990
51. McLachlin SM, Srigley JR: Prostatic tissue in mature cystic teratomas of the ovary. Am J Surg Pathol 16: 780-784, 1992
52. Buzzi A, Crescini C, Sonzogni A, Pezzica E: Prostatic tissue in a cystic teratoma of the ovary. Minerva Ginecol 46: 49-51, 1994
53. Frazier HA, Humphrey PA, Burchette JL, Paulson DF: Immunorcactive prostate-specific antigen in male periurethral glands. J Urol 147: 246-248, 1992
54. van Krieken JH: Prostate marker immunoreactivity in salivary gland neoplasm. A rare pitfall in immunohistochemistry. Am J Surg Pathol 17: 410-414, 1993
55. James GK, Pudek M, Berean DW, Diamandis EP: Salivary duct carcinoma secreting prostate-specific antigen. Am J Clin Pathol 106: 242-247, 1996
56. Elgamal AA, van de Voorde W, van Poppel H, Leuweryns J, Baert L: Immunohistochemical localization of prostate-specific markers within the accessory male sex gland of Cowper, Littre, and Morgagni. Urology 44: 84-90, 1994
57. Diamandis EP, Yu H, Sutherland DJA: Detection of prostate-specific antigen immunoreactivity in breast tumours. Breast Cancer Res Treat 32: 301-310, 1994
58. Monne M, Croce CM, Yu H, Diamandis EP: Molecular characterization of prostate-specific antigen mRNA expressed in breast tumors. Cancer Res 54: 6344-6347, 1994
59. Yu H, Diamandis EP, Sutherland DJA: Immunoreactive prostate-specific antigen levels in female and male breast tumours and its association with steroid hormone receptors and patient age. Clin Biochem 27: 75-79, 1994
60. Wu JT, Zhang ME, Wilson LW, Lyons BW, Wu LL, Stephenson R: PSA immunoreactivity detected in LNCaP cell medium, breast tumor cytosol, and female scrum. J Clin Lab Anal 9: 243-251, 1995
61. Filella X, Molina R, Alcover J, Menendez V, Gimenez N, Jo J, Carretero P, Ballesta AM: Prostate-specific antigen detection by ultrasensitive assay in samples from women. Prostate 29: 311-316, 1996
62. Yu H, Diamandis EP, Levesque M, Giai M, Roagna R, Ponzone R, Sismondi P, Monne M, Croce C: Prostate-specific antigen in breast cancer, benign breast disease and normal breast tissue. Breast Cancer Res Treat 40: 171-178, 1996
63. Zarghami N, Diamandis EP: Detection of prostate-specific antigen mRNA and protein in breast tumours. Clin Chem 42: 361-366, 1996
64. Bodey B, Bodey Jr B, Kaiser HE: Immunocytochemical detection of prostate-specific antigen expression in human breast carcinoma cells. Anticancer Res 17: 2577-2582, 1997
65. Howarth DJC, Aronson IB, Diamandis EP: Immunohistochemical localization of prostate-specific antigen in benign and malignant breast tissues. Br J Cancer 75: 1646-1651, 1997
66. Alanen KA, Kuopio T, Koskinen PJ, Nevalainen TJ: Immunohistochcmical labeling for prostate-specific antigen in non-prostatic tissues. Path Res Pract 192: 233-237, 1996
67. Clements JA, Mukhtar A: Glandular kallikreins and prostate-specific antigen are expressed in the human endometrium. J Clin Endocrinol Metab 78: 1536-1539, 1994
68. Sleater JP, Ford MJ, Beers BB: Extra-mammary Paget's disease associated with prostate carcinoma. Hum Pathol 25: 615-617, 1994
69. Levesque M, Yu H, D'Costa M, Diamandis EP: Prostate-specific antigen expression by various tumors. J Clin Lab Anal 9: 123-128, 1995
70. Yu H, Diamandis EP: Prostate-specific antigen reactivity in amniotic fluid. Clin Chem 41: 204-210, 1995
71. Filella X, Molina R, Alcover J, Carretero P, Ballesta AM: Detection of nonprostatic PSA in serum and non-serum samples from women. Int J Cancer 68: 424-427, 1996
72. Melegos DN, Yu H, Allen LC, Diamandis EP: Prostate-specific antigen in amniotic fluid of normal and abnormal pregnancies. Clin Chem 29: 555-562, 1996
73. Smith MR, Biggar S, Hussain M: Prostate-specific antigen messenger RNA is expressed in non-prostate cells: implications for detection of micrometastases. Cancer Res 55: 2640-2644, 1995
74. Yu H, Diamandis EP, Monne M, Croce C: Oral contraceptive-induced expression of prostate-specific antigen in the female breast. J Biol Chem 270: 6615-6618, 1995
75. Levesque M, Yu H, D'Costa M, Tadross L, Diamandis EP: Immunoreactive prostate-specific antigen in lung tumours. J Clin Lab Anal 9: 375-379, 1995
76. Zarghami N, D'Costa M, Tsuyuki D, Asa SL, Diamandis EP: Expression of the prostate-specific antigen gene by lung tissue. Clin Cancer Res 3: 1201-1206, 1997
77. Zarghami N, Levesque M, D'Costa M, Angelopoulou K, Diamandis EP: Frequency of expression of prostate-specific antigen mRNA in lung tumours. Am J Clin Pathol 108: 184-190, 1997
78. Yu H, Diamandis EP: Prostatic-specific antigen in milk of lactating women. Clin Chem 41: 54-58, 1995
79. Yu H, Diamandis EP, Levesque M, Asa S, Monne M, Croce CM: Expression of the prostate-specific antigen gene by a primary ovarian carcinoma. Cancer Res 55: 1603-1606. 1995
80. Kuopio T, Ekfors TO, Nikkanen V, Nevalainen TJ: Acinar cell carcinoma of the pancreas: report of three cases. APMIS 103: 69-78, 1995
81. Giai M, Yu H, Roagna R, Ponzone R, Katsaros D, Levesque MA, Diamandis EP: Prostate-specific antigen in serum of women with breast cancer. Br J Cancer 72: 728-731, 1995
82. Lehrer S, Terk M, Piccoli SP, Song HK, Lavagnini P, Luderer AA: Reverse transcriptase-polymerase chain reaction for prostate-specific antigen may be a prognostic indicator in breast cancer. Br J Cancer 74: 871-873, 1996
83. Melegos DN, Diamandis EP: Diagnostic value of molecular forms of prostate-specific antigen for female breast cancer. Clin Biochem 29: 193-200, 1996
84. Borchert GH, Melegos DN, Tomlinson G, Giai M, Roagna R, Ponzone R, Sgro L, Diamandis EP: Molecular forms of prostate-specific antigen in the serum of women with benign and malignant breast diseases. Br J Cancer 76: 1087-1094, 1997
85. Black MH, Giai M, Ponzone R, Sismondi P, Yu H, Diamandis EP: Serum total and free prostate-specific antigen for breast cancer diagnosis in women. Clin Cancer Res (in press)
86. Yu H, Diamandis EP: Measurement of serum prostate-specific antigen levels in females and in prostatectomized males with an ultrasensitive immunoassay technique. J Urol 153: 1004-1008, 1995
87. Mannello F, Bianchi G, Gazzanelli G: Immunoreactivity of prostate-specific antigen in plasma and saliva of healthy women. Clin Chem 42: 1110-1111, 1996
88. Zarghami N, Grass L, Sauter ER, Diamandis EP: Prostate-specific antigen levels in serum during the menstrual cycle. Clin Chem 43: 1862-1867, 1997
89. Melegos DN and Diamandis EP: Is prostate-specific antigen present in female serum? Clin Chem 44: 691-692, 1998
90. Diamandis EP, Yu H, Lopez-Otin C: Prostate-specific antigen - a new constituent of breast cyst fluid. Breast Cancer Res Treat 38: 259-264, 1996
91. Lai LC, Erbas H, Lennard TW, Peaston RT: Prostate-specific antigen in breast cyst fluid: possible role of prostate-specific antigen in hormone-dependent breast cancer. Int J Cancer 66: 743-746, 1996
92. Mannello F, Bocchiotti G, Bianchi G, Marcheggiani F, Gazzanelli G: Quantification of prostate-specific antigen immunoreactivity in human breast cyst fluids. Breast Cancer Res Treat 38: 247-252, 1996
93. Borchert GH, Yu H, Tomlinson G, Giai M, Roagna R, Ponzone R, Sgro L, Diamandis EP: Prostate-specific antigen molecular forms in breast cyst fluid and serum of women with fibrocystic breast disease. J Clin Lab Anal 13: 75-81, 1999
94. Foretova L, Garber JE, Sadowsky NL, Verselis SJ, Li FP: Prostate-specific antigen in nipple aspirates. Lancet 347: 1631, 1996
95. Sauter ER, Daly M, Lenahan K, Ehya H, Engstrom PF, Sorling A, Bonney G, Yu H, Diamandis EP: Prostate-specific antigen levels in nipple aspirate fluid correlate with breast cancer risk. Cancer Epidemiol Biomarkers Prev 5: 967-970,1996
96. Sauter ER, Babb J, Daly M, Engstrom PF, Ehya H, Malick J, Diamandis EP: Prostate-specific antigen production in the female breast: association with progesterone. Cancer Epidemiol Biomarkers Prev 7: 315-320, 1998
97. Mannello F, Miragoli G, Bianchi G, Gazzanelli, G: Prostate-specific antigen in ascitic fluid. Clin Chem 43: 1461-1462,1997
98. Melegos DN, Freedman MS, Diamandis EP: Prostate-specific antigen in cerebrospinal fluid. Clin Chem 43: 855, 1997
99. Mannello F, Miragoli G, Blanchi G, Gazzanelli G: Immunoreactive prostate-specific antigen in pleural effusions. Clin Chem 43: 847-848, 1997
100. Melegos DN, Yu H, Ashok M, Wang C, Stanczyk F, Diamandis EP: Prostate-specific antigen in female serum, a potential new marker for androgen excess. J Clin Endo Metab 82: 777-780, 1997
101. Mannello F, Malatesta M, Luchetti F, Papa S, Battistelli S, Gazzanelli G: Immunoreactivity, ultrastructural localization, and transcript expression of prostate-specific antigen in human neuroblastoma cell lines. Clin Chem 45: 78-84, 1999
102. Cleutjens KBIM, van der Korput HAGM, van Eekelen CCEM, van Rooij HCJ, Faber PW, Trapman J: An androgen response element in a far upstream enhancer region is essential for high, androgen-regulated activity of the prostate-specific antigen promoter. Mol Endocrinol 11: 148-161, 1997
103. Beato M: Gene regulation by steroid hormones. Cell 56: 335-344, 1989
104. Shan J-D, Porvari K, Ruokonen M, Karhu A, Launonen V, Hedberg P, Oikarinen J, Vihko P: Steroid-involved transcriptional regulation of human genes encoding prostatic acid phosphatase, prostate-specific antigen, and prostate-specific glandular kallikrein. Endocrinol 138: 3764-3770, 1997
105. Zarghami N, Grass L, Diamandis EP: Steroid hormone regulation of prostate-specific antigen gene expression in breast cancer. Br J Cancer 75: 579-588, 1997
106. Killian CS, Corral DA, Kawinski E, Constantine RI: Mitogenic response of osteoblast cells to prostate-specific antigen suggests an activation of latent TGF-β and a proteolytic modulation of cell adhesion receptors. Biochem Biophys Res Comm 192: 940-947, 1993
107. Yoshida E, Ohmura S, Sugiki M, Maruyama M, Minara H: Prostate-specific antigen activates single-chain urokinase-type plasminogen activator. Int J Cancer 63: 863-865, 1995
108. Frenette G, Tremblay RR, Lazure C, Dube JY: Prostatic kallikrein hK2, but not prostate-specific antigen (hK3) activates single-chain urokinase-type plasminogen activator. Int J Cancer 71: 897-899, 1997
109. Webber MM, Waghray A, Bello D: Prostate-specific antigen, a serine protease, facilitates human prostate cancer cell invasion. Clin Cancer Res 1: 1089-1094, 1995
110. Cohen P, Peehl DM, Graves HCB, Rosenfeld RG: Biological effects of prostate-specific antigen as an insulin-like growth factor binding protein-3 protease. J Endocrinol 142: 407-415, 1994
111. Zaviacic M, Ablin RJ: The female prostate. J. Natl Cancer Inst 90: 713-714, 1998
112. Yu H, Levesque MA, Clark GM, Diamandis EP: Prognostic value of prostate-specific antigen for women with breast cancer: a large United States cohort study. Clin Cancer Res 4: 1489-1497, 1998
113. Tsuyuki D, Grass L, Diamandis EP: Frequent detection of mutations in the 5′ flanking region of the prostate-specific antigen gene in female breast cancer. Eur J Cancer 33: 1851-1854, 1997
114. Majumdar S and Diamandis EP: The promoter and the enhancer region of the KLK3 (prostate-specific antigen) gene is frequently mutated in breast tumours and in breast carcinoma cell lines. Br J Cancer 79: 1594-1602, 1999
115. Yu H, Diamandis EP, Zarghami N, Grass L: Induction of prostate-specific antigen production by steroids and tamoxifen in breast cancer cell lines. Br Cancer Res Treat 32: 291-300, 1994
116. Kogan I, Ballinger JR, Redshaw R, Diamandis EP, Melegos DN, Kuba RM, Rauth AM: Prostate-specific antigen induction by a steroid hormone in T47D cells growing in SCID mice. Breast Cancer Res Treat 48: 73-80, 1998
117. Yu H, Giai M, Diamandis EP, Katsaros D, Sutherland DJA, Levesque MA, Roagna R, Ponzone R, Sismondi P: Prostatic-specific antigen is a new favourable prognostic indicator for women with breast cancer. Cancer Res 55: 2104-2110, 1995
118. Hall RE, Clements JA, Birrell SN, Tilley WD. Prostate-specific antigen and gross cystic disease fluid protein-15 are co-expressed in androgen receptor-positive breast tumours. Br J Cancer 78: 360-365, 1998
119. Foekens JA, Diamandis EP, Yu H, Look MP, Meijer-van Gelder ME, van Putten WLJ, Klijn JGM: Expression of prostate-specific antigen (PSA) correlates with poor response to tamoxifen therapy in recurrent breast cancer. Br J Cancer 79: 888-894, 1999
120. Zangerle PF, Spyratos F, Le Doussal V, Noel G, Hacene K, Hendrick JC, Gest J, Franchimont P: Breast cyst fluid proteins and breast cancer. Ann NY Acad Sci 464: 331-349, 1986
121. Bradshaw HL, Fleishre M, Breed CN, Chasalow FI: Biochemical classification of patients with gross cystic breast disease. Ann NY Acad Sci 586: 12-16, 1990
122. Randell EW, Diamandis EP, Ellis G: Serum prostate-specific antigen measured in children from birth to age 18 years. Clin Chem 42: 420-423, 1996
123. Forest MG, Sizonenko PC, Cathiard AM, Bertrand J: Hypophysogonadal function in humans during the first year of life. J Clin Invest 53: 819-828, 1974
124. Katsaros D, Melegos DN, Diamandis EP: Prostate-specific antigen production by breast tumors after induction with oral contraceptives. Clin Biochem 31: 285-288, 1998
125. Diamandis EP, Helle SI, Yu H, Melegos DN, Lundgren S, Lonning PE: Prognostic value of plasma prostate-specific antigen following megestrol acetate treatment in patients with metastatic breast cancer. Cancer 85: 891-898, 1999
126. Black MH, Grass CL, Leinonen J, Stenman U-H, Diamandis EP: Characterization of monoclonal antibodies for prostate-specific antigen (PSA) and development of highly sensitive free PSA assays. Clin Chem 1999 45: 347-354, 1999
127. Lambert-Messerlian GM, Canick JA, Melegos DN, Diamandis EP: Increased concentrations of prostate-specific antigen in maternal serum from pregnancies affected by fetal Down Syndrome. Clin Chem 44: 205-208, 1998
128. Spencer K, Carpenter P: Is prostate-specific antigen a marker for pregnancies affected by Down syndrome? Clin Chem 44: 2362-2365, 1998
129. Reiss M, Barcellos-Hoff MH: Transforming growth factor-beta in breast cancer: a working hypothesis. Breast Cancer Res Treat 45: 81-95, 1997
130. Helle SI, Lonning PE: Insulin-like growth factors in breast cancer. Acta Oncol Supp 5: 19-22, 1996
131. Gill ZP, Perks CM, Newcomb PV, Holly JMP: Insulin-like growth factor-binding protein (IGFBP-3) predisposes breast cancer cells to programmed cell death in a non-IGF-dependent manner. J Biol Chem 272: 25602-25607, 1997
132. Dauvois S, Geng CS, Levesque C, Merand Y, Labrie F: Additive inhibitory effects of an androgen and the antiestrogen EM-170 on estradiol-stimulated growth of human ZR-75-1 breast tumors in athymic mice. Cancer Res 51: 3131-3135, 1991
133. Balbay MD, Juang P, Llansa N, Williams S, McConkey D, Fidler IJ, Pettaway CA: Stable transfection of human prostate cancer cell line PC-3 with prostate-specific antigen induces apoptosis both in vivo and in vitro (Abstract). Proc Am Assoc Cancer Res 40: 225-226, 1999
134. Iwamura M, Hellman J, Cockett ATK, Lilja H, Gershagen S: Alteration of the hormonal bioactivity of parathyroid hormone-related protein (PTHrP) as a result of limited proteolysis by prostate-specific antigen. Urology 48: 317-325, 1996
135. Wulf GG, Jurgens B, Liersch T, Gatzemeier W, Rauschecker H, Buske C, Hufner M, Hiddemann W, Wormann B: Reverse transcriptase/polymerase chain reaction analysis of parathyroid hormone-related protein for the detection of tumor cell dissemination in the peripheral blood and bone marrow of patients with breast cancer. Cancer Res Clin Oncol 123: 514-521, 1997
136. Diamandis EP:. . . . And secreted tumour suppressors. Nature Genet 13: 268, 1996
137. Rehbock J, Buchinger P, Hermann A, Figueroa C: Identification of immunoreactive tissue kallikrein in human ductal breast carcinomas. J Cancer Res Clin Oncol 121: 64-68, 1995
138. Hermann A, Buchinger P, Rehbock J: Visualization of tissue kallikrein in human breast carcinoma by two-dimensional western blotting and immunohistochemistry. Biol Chem Hoppe-Seyler 376: 365-370, 1995
139. Hsieh M-L, Charlesworth C, Goodmanson M, Zhang S, Seay T, Klee GG, Tindall DJ, Young CYF: Expression of human prostate-specific glandular kallikrein protein (hK2) in the breast cancer cell line T47-D. Cancer Res 57: 2651-2656, 1997
140. Black MH, Magklara A, Obiezu CV, Levesque MA, Sutherland DJA, Tindall DJ, Young CYF, Sauter ER, Diamandis EP: Expression of a prostate-associated protein, human glandular kallikrein (hK2), in breast tumours and in normal breast secretions. Br J Cancer (in press)
141. Magklara A, Scorilas A, Lopez-Otin C, Vizoso F, Ruibal A, Diamandis EP: Human glandular kallikrein (hK2) in breast milk, amniotic fluid, and breast cyst fluid. Clin Chem (in press)
142. Liu XL, Wazer DE, Watanabe K, Band V: Identification of a novel serine protease-like gene, the expression of which is down-regulated during breast cancer progression. Cancer Res 56: 3371-3379, 1996
143. Goyal J, Smith KM, Cowan JM, Wazer DE, Lee SW, Band V: The role for NES1 serine protease as a novel tumor suppressor. Cancer Res 58: 4782-4786, 1998
144. Parish DC: Prostate-specific antigen in the breast. Endo-Rel Cancer 5: 223-229, 1998
145. Lopez-Otin C, Diamandis EP: Breast and prostate cancer: An analysis of common epidemiological, genetic, and biochemical features. Endo Rev 19: 365-396, 1998
146. Diamandis EP, Yu H: Nonprosatic sources of prostate-specific antigen. Urol Clin N Am 24: 275-282, 1996